866-997-4948(US-Canada Toll Free)

Anaphylaxis - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 38 Pages

Anaphylaxis - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anaphylaxis Pipeline Review, H2 2016, provides an overview of the Anaphylaxis (Immunology) pipeline landscape.

Anaphylaxis is a severe, potentially life-threatening allergic reaction. Anaphylaxis symptoms include dizziness, nausea, vomiting or diarrhea, feeling of warmth, constriction of the airways and a swollen tongue or throat. Risk factors include personal history of anaphylaxis, allergies or asthma and family history. Treatment includes beta-agonist, antihistamines and cortisone.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anaphylaxis Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Anaphylaxis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anaphylaxis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Anaphylaxis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn and Preclinical stages are 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.Anaphylaxis.

Anaphylaxis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Anaphylaxis (Immunology).
- The pipeline guide reviews pipeline therapeutics for Anaphylaxis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Anaphylaxis (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Anaphylaxis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Anaphylaxis (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Anaphylaxis (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Anaphylaxis (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Anaphylaxis Overview 6
Therapeutics Development 7
Pipeline Products for Anaphylaxis - Overview 7
Pipeline Products for Anaphylaxis - Comparative Analysis 8
Anaphylaxis - Therapeutics under Development by Companies 9
Anaphylaxis - Therapeutics under Investigation by Universities/Institutes 10
Anaphylaxis - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Anaphylaxis - Products under Development by Companies 13
Anaphylaxis - Products under Investigation by Universities/Institutes 14
Anaphylaxis - Companies Involved in Therapeutics Development 15
Adamis Pharmaceuticals Corp 15
MannKind Corp 16
Monosol Rx LLC 17
Anaphylaxis - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
epinephrine - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
epinephrine - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
epinephrine - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
epinephrine - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
ET-523 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Monoclonal Antibody to Antagonize FcgR1 for Inflammatory and Autoimmune Disorders - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Monoclonal Antibody to Antagonize FcgRIIa for Inflammatory and Autoimmune Disorders - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Anaphylaxis - Dormant Projects 35
Anaphylaxis - Product Development Milestones 36
Featured News & Press Releases 36
Sep 10, 2013: Novel Nasal Epinephrine Shows Comparable Absorption to EpiPen(R) in a Feasibility Study 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 37
Disclaimer 38

List of Tables
Number of Products under Development for Anaphylaxis, H2 2016 7
Number of Products under Development for Anaphylaxis - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Products under Investigation by Universities/Institutes, H2 2016 14
Anaphylaxis - Pipeline by Adamis Pharmaceuticals Corp, H2 2016 15
Anaphylaxis - Pipeline by MannKind Corp, H2 2016 16
Anaphylaxis - Pipeline by Monosol Rx LLC, H2 2016 17
Assessment by Monotherapy Products, H2 2016 18
Number of Products by Stage and Target, H2 2016 20
Number of Products by Stage and Mechanism of Action, H2 2016 22
Number of Products by Stage and Route of Administration, H2 2016 24
Number of Products by Stage and Molecule Type, H2 2016 26
Anaphylaxis - Dormant Projects, H2 2016 35

List of Figures
Number of Products under Development for Anaphylaxis, H2 2016 7
Number of Products under Development for Anaphylaxis - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy Products, H2 2016 18
Number of Products by Targets, H2 2016 19
Number of Products by Stage and Targets, H2 2016 19
Number of Products by Mechanism of Actions, H2 2016 21
Number of Products by Stage and Mechanism of Actions, H2 2016 21
Number of Products by Routes of Administration, H2 2016 23
Number of Products by Stage and Routes of Administration, H2 2016 23
Number of Products by Molecule Types, H2 2016 25
Number of Products by Stage and Molecule Types, H2 2016 25

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *